Drugs / FX06
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04618042 | Nov 2020 → May 2021 | COVID-19, acute respiratory distress syndrome, pneumonia | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 2 | NCT00326976 | Aug 2006 → Nov 2007 | coronary artery disorder, myocardial infarction, myocardial ischemia | Fibrex Medical Research & Development GmbH | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-03 | Partner Therapeutics, Inc. | Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications partnertx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FX06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04618042 ↗ |
| Known as | Bbeta15-42 | “FX06 (a Fibrin Derived Peptide Bbeta15-42)” NCT00326976 ↗ |
| Modality | Peptide | “FX06, a naturally occurring peptide derived from human fibrin” PMID 19232907 ↗ Feb 2009 |
| Route | Intravenous | “FX06 or matching placebo was given as intravenous bolus at reperfusion.” PMID 19232907 ↗ Feb 2009 |